1. |
2. EditorialDavid Ožura, 2024, predgovor, uvodnik, spremna beseda Ključne besede: medical journals, oncology, open access, editorial, bibliographic databases, citation index
Objavljeno v DiRROS: 26.07.2024; Ogledov: 167; Prenosov: 132
 Celotno besedilo (838,80 KB)
Gradivo ima več datotek! Več... |
3. Imaging microvascular changes in nonocular oncological clinical applications by optical coherence tomography angiography : a literature reviewRok Hren, Gregor Serša, Urban Simončič, Matija Milanič, 2023, pregledni znanstveni članek Ključne besede: optical coherence tomography, angiography, endoscopy, oncology, skin carcinoma
Objavljeno v DiRROS: 26.07.2024; Ogledov: 387; Prenosov: 165
Celotno besedilo (4,95 MB)
Gradivo ima več datotek! Več... |
4. |
5. Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheresBarbara Breznik, Meng-Wei Ko, Christopher Tse, Po-Chun Chen, Emanuela Senjor, Bernarda Majc, Anamarija Habič, Nicolas Angelillis, Metka Novak, Vera Župunski, Jernej Mlakar, David Nathanson, Anahid Jewett, 2022, izvirni znanstveni članek Povzetek: Glioblastomas remain the most lethal primary brain tumors. Natural killer (NK) cell-based therapy is a promising immunotherapeutic strategy in the treatment of glioblastomas, since these cells can select and lyse therapy-resistant glioblastoma stem-like cells (GSLCs). Immunotherapy with super-charged NK cells has a potential as antitumor approach since we found their efficiency to kill patient-derived GSLCs in 2D and 3D models, potentially reversing the immunosuppression also seen in the patients. In addition to their potent cytotoxicity, NK cells secrete IFN-γ, upregulate GSLC surface expression of CD54 and MHC class I and increase sensitivity of GSLCs to chemotherapeutic drugs. Moreover, NK cell localization in peri-vascular regions in glioblastoma tissues and their close contact with GSLCs in tumorospheres suggests their ability to infiltrate glioblastoma tumors and target GSLCs. Due to GSLC heterogeneity and plasticity in regards to their stage of differentiation personalized immunotherapeutic strategies should be designed to effectively target glioblastomas.
Ključne besede: glioblastoma, natural killer cells, translational oncology
Objavljeno v DiRROS: 16.07.2024; Ogledov: 238; Prenosov: 208
Celotno besedilo (10,81 MB)
Gradivo ima več datotek! Več... |
6. ▫$[^{18}\mathrm F]$▫FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumabDamijan Valentinuzzi, Martina Vrankar, Nina Boc, Valentina Ahac, Žiga Zupančič, Mojca Unk, Katja Škalič, Ivana Žagar, Andrej Studen, Urban Simončič, Jens C. Eickhoff, Robert Jeraj, 2020, izvirni znanstveni članek Ključne besede: medical physics, medical imaging, oncology
Objavljeno v DiRROS: 15.07.2024; Ogledov: 234; Prenosov: 63
Celotno besedilo (461,33 KB) |
7. Impact of COVID-19 on cancer diagnosis and management in Slovenia : preliminary resultsVesna Zadnik, Ana Mihor, Sonja Tomšič, Tina Žagar, Nika Bric, Katarina Lokar, Irena Oblak, 2020, izvirni znanstveni članek Ključne besede: covid-19, oncology, oncology diagnosis, pandemic
Objavljeno v DiRROS: 12.07.2024; Ogledov: 245; Prenosov: 104
Celotno besedilo (291,69 KB)
Gradivo ima več datotek! Več... |
8. |
9. Do double-expressor high-grade B-cell lymphomas really need intensified treatment : a report from the real-life series of high-grade B-cell lymphomas treated with different therapeutic protocols at the Institute of Oncology LjubljanaLučka Boltežar, Samo Rožman, Gorana Gašljević, Biljana Grčar-Kuzmanov, Barbara Jezeršek Novaković, 2024, izvirni znanstveni članek Povzetek: High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed. Only patients with double-expressor lymphoma (DEL), double-hit lymphoma (DHL), or triple-hit lymphoma (THL) were included. Demographic and clinical parameters were assessed, as well as progression-free survival (PFS) and overall survival (OS). In total, 161 cases out of 309 (161/309; 52,1%) were classified as DEL. Sixteen patients had DHL, MYC/BCL2 rearrangement was observed in eleven patients, and MYC/BCL6 rearrangement was observed in five patients. Five patients were diagnosed with THL. Out of 154 patients (according to inclusion/exclusion criteria) included in further evaluation, one-hundred and thirty-five patients had double-expressor lymphoma (DEL), sixteen patients had DHL, and three patients had THL. In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The median follow-up was 22 months. The 5-year OS for the whole DEL group was 57.1% (95% CI 45.9–68.3%) and the 5-year PFS was 76.5% (95% CI 72.6–80.4%). The log-rank test disclosed no differences in survival between treatment groups (p = 0.712) while the high-risk international prognostic index (IPI) carried a significantly higher risk of death (HR 7.68, 95% CI 2.32–25.49, p = 0.001). The 5-year OS for DHL patients was 32.4% (95% CI 16.6–48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients.
Ključne besede: lymphoma, double-expressor lymphoma, oncology
Objavljeno v DiRROS: 18.04.2024; Ogledov: 396; Prenosov: 204
Celotno besedilo (1004,13 KB)
Gradivo ima več datotek! Več... |
10. |
